Compare IIPR & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IIPR | NTLA |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | 2016 | 2016 |
| Metric | IIPR | NTLA |
|---|---|---|
| Price | $51.60 | $12.19 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 19 |
| Target Price | ★ $64.50 | $24.00 |
| AVG Volume (30 Days) | 248.3K | ★ 3.5M |
| Earning Date | 11-02-2026 | 11-05-2026 |
| Dividend Yield | ★ 14.43% | N/A |
| EPS Growth | N/A | ★ 27.43 |
| EPS | ★ 2.39 | N/A |
| Revenue | ★ $265,955,000.00 | $67,671,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.98 | $143.36 |
| P/E Ratio | $22.09 | ★ N/A |
| Revenue Growth | N/A | ★ 16.92 |
| 52 Week Low | $44.58 | $7.95 |
| 52 Week High | $65.38 | $28.24 |
| Indicator | IIPR | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 26.09 | 50.89 |
| Support Level | $48.51 | $11.51 |
| Resistance Level | $51.68 | $12.97 |
| Average True Range (ATR) | 1.02 | 0.61 |
| MACD | -0.36 | 0.01 |
| Stochastic Oscillator | 0.34 | 58.32 |
Innovative Industrial Properties Inc is a real estate investment trust focused on the acquisition, ownership and management of specialized industrial and commercial properties in the United States. Its properties are prominently leased to state-licensed operators for their regulated cannabis facilities. The company conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by its Operating Partnership, directly or through subsidiaries. Its segments are: Cannabis Portfolio and Life Science Portfolio, with the majority of revenue coming from the Cannabis Portfolio segment, which involves acquiring, developing, and leasing real estate to regulated cannabis operators on long-term triple-net leases.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.